Medical Marijuana, Inc. Subsidiary HempMeds® Brasil’s Sold-Out Doctor Symposium on Medical Cannabis Garners Vast Media Coverage Across Brazil

SAN DIEGO, Aug. 23, 2017  — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil held a successful, sold-out Doctor Symposium in Sao Paulo, Brazil on August 15, with 50 doctors in attendance, which garnered vast media coverage across Brazil.

An August 18, 2017 online article from Rio de Janeiro-based Brazilian newspaper O Globo “HempMeds® Brasil reune medicos e pesquisadores para discutir uso terapeutico do canabidiol,” or “HempMeds® Brasil brings together physicians and researchers to discuss therapeutic use of cannabidiol,” which was picked up by several other major news outlets across the Country, discussed how the Symposium successfully brought together doctors from different specialties interested in learning about the medical value of CBD and how to legally import CBD into the country and prescribe it for patients.

The event featured renowned medical experts and pioneers in the field like Dr. Saul Garza Morales, pediatric researcher and neurologist in Mexico, and Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc., who both shared on the specific therapeutic benefits of CBD, as well as gaining access to medical cannabis for improving health and quality of life. Also in attendance was CBD parent advocate Norberto Fischer, who shared his family’s story of how their fight to save daughter Anny helped legalize medical cannabis in Brazil.

“Our Doctor’s Symposium in Sao Paulo was a major success and we were encouraged to witness the convergence of doctors interested in learning more about the therapeutic benefits of CBD, as well as families sharing their stories about how our products have helped change their children’s lives,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “These types of events are critical for improving the treatment options for numerous medical indications including autism, Parkinson’s, epilepsy, cancer, and more.”

Additionally, as demand grows for the Company’s CBD hemp oil across the Country, HempMeds® Brasil is looking to expand by opening an office on the ground in Rio de Janeiro, Brazil by the end of 2017.

HempMeds® Brasil is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. Most recently in February 2017, for the filling of a prescription for the first time for the Company’s hemp CBD oil product RSHO™ to treat patients in the Country suffering from Multiple Sclerosis. Additionally, doctors in Brazil can prescribe RSHO™ for any condition and HempMeds® Brasil has worked with several cases including patients suffering from:

Epilepsy Alzheimer’s
Psoriasis Migraine
Pain Diabetes
Cancer Amyotrophic Lateral Sclerosis

About Medical Marijuana, Inc. 
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically-sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About HempMeds® Brasil 
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for multiple conditions including; Epilepsy, Parkinson’s, Chronic Pain, Psoriasis, Cancer, Alzheimer’s, Diabetes, ALS, Multiple Sclerosis and Migraines. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
[email protected]